Business Context and Reporting Period
This Form 8-K is filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc.) on June 20, 2018, with the earliest event reported on that date. The filing documents corporate governance changes and the completion of the Company's initial public offering (IPO) effective June 25, 2018.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, or debt metrics. The only financial data disclosed relates to the IPO:
- Shares Sold: 6,666,667 shares of Common Stock.
- Offering Price: $15.00 per share.
- Gross Proceeds: Approximately $100.0 million.
Material Changes
The Company underwent significant structural changes in connection with its IPO:
- Capital Structure: Authorized 150,000,000 shares of Common Stock and 10,000,000 shares of undesignated preferred stock. All references to previously existing preferred stock were eliminated.
- Governance: Amended and Restated By-Laws became effective, eliminating the ability of stockholders to take action by written consent or call special meetings. New procedures for stockholder proposals and director nominations were established.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of specific risks and contingencies. It is a procedural report confirming the effectiveness of the Restated Certificate of Incorporation and By-Laws and the completion of the IPO.
Investor Verification Checklist
- Verify the final use of the approximately $100.0 million in gross IPO proceeds.
- Confirm the exact number of shares outstanding post-IPO, including any underwriter over-allotment exercise.
- Review the full text of the Amended and Restated By-Laws (Exhibit 3.2) for specific restrictions on shareholder rights.
- Check subsequent filings for the Company's first audited financial statements, as this 8-K does not contain historical financial data.